IMNM

15.6905.54%
IB

Isaac Barchas

Lead Independent Director

Mr. Isaac Barchas, J.D., serves as a Director of Courage Therapeutics, Inc. Mr. Barchas serves as a MD & Founding Partner at Arsenal Bridge Ventures. He serves as Lead Independent Director of Immunome, Inc. since October, 2023. Mr. Barchas serves as an Independent Director at Sustainable Opportunities Acquisition Corp. since 2020. He serves as Managing Partner and Director of Austin Technology Incubator. Mr. Barchas works with companies across all of the ATI verticals namely, information technology, wireless and clean energy. In addition, he is responsible for ATI’s strategic direction and for evolving the ATI economic model. Mr. Barchas also supports the global commercialization programs run out of the IC2 Institute. Mr. Barchas is the President and Chief Executive Officer of Research Bridge Partners (“RBP”), a socially-driven investment company, which he founded in 2016. Prior to joining ATI, he worked at McKinsey & Company for few years, where Mr. Barchas focused on business building (start-up and spin-out support) in a variety of industries, including biotechnology, software, wireless telecoms and Internet retail. He previously served a CEO of Research Bridge Partners, which he co-founded with Reid Hoffman and continues to serve a special advisor to the company. He was also one of the leaders at McKinsey’s North American healthcare practice. Mr. Barchas was a Member (at various times) at the McKinsey offices in Chicago, Sydney, Auckland, Dallas and London. He has also published in the Washington Post, the Wall Street Journal and the Chicago Tribune, among other outlets. Mr. Barchas serves as Board Chairman and Secretary of Morph Immune, Inc. Mr. Barchas earned a J.D. (honors) and M.A. (Century Fellowship) from The University of Chicago. He received an A.B. from Stanford University (honors and Phi Beta Kappa).

Positions